TCM Life Science Inc. raises indefinite capital under Reg D 506(b) in Delaware biotech debut
TCM Life Science Inc., a Delaware biotechnology corporation incorporated in 2026, filed its first Form D on October 26, 2026, disclosing an indefinite offering with $17K sold to 2 investors as of October 12, 2026. The company is led by Ya-Chun Wang (President and Director) and Huan-Chin Hsu (Director) and lists no placement agent.
Note: Entity incorporated October 2026, same month as first sale; first-time EDGAR filer; indefinite offering amount; no placement agent listed.
How this compares
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
People on the filing
| Ya-Chun Wang | Executive Officer, Director |
| Huan-Chin Hsu | Director |
[email protected] · observed Work emails for the people on the filing, where the firm publishes or patterns them, labelled by confidence — subscribers
Signed by Ya-Chun Wang, President.
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.